These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 16613101

  • 1. [Use of spironolactone and indapamide in the treatment of low-renin arterial hypertension].
    Naudzhunas A, Bagdonas G, Yankauskene L, Kazanavichus G.
    Ter Arkh; 2006; 78(2):61-4. PubMed ID: 16613101
    [Abstract] [Full Text] [Related]

  • 2. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S, Bernheim J, Podjarny E.
    Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
    [Abstract] [Full Text] [Related]

  • 3. [Correlations between blood pressure, blood volume and plasma renin during therapy with diuretics in essential hypertension. Comparison between the mineralocorticoid antagonist spironolactone and the "loop" diuretic mefruside].
    Beretta-Piccoli C, Weidmann P, de Châtel R, Hirsch D, Reubi FC.
    Schweiz Med Wochenschr; 1977 Jan 29; 107(4):104-15. PubMed ID: 834983
    [Abstract] [Full Text] [Related]

  • 4. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
    Hood SJ, Taylor KP, Ashby MJ, Brown MJ.
    Circulation; 2007 Jul 17; 116(3):268-75. PubMed ID: 17606839
    [Abstract] [Full Text] [Related]

  • 5. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A, Mahgoub M, Hall M, Feely J.
    Am J Hypertens; 2005 Dec 17; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [Abstract] [Full Text] [Related]

  • 6. [Plasma renin activity in essential hypertension: different short- und long-term effects of diuretics (author's transl)].
    Esch I, Placheta P, Gaul G.
    Wien Klin Wochenschr; 1976 Jun 25; 88(13):415-8. PubMed ID: 824860
    [Abstract] [Full Text] [Related]

  • 7. [Clinical and vascular effects of ACE inhibitor enalapril in combination with thiaside-like diuretic indapamide in hypertensive outpatients. Results of the multicenter trial POEMA].
    Belenkov IuN, Ageev FT, Orolova IaA, Abrosimova OIu, Volkova EG, Gapon LI, Katel'nitskaia LI, Kondari AO, Patrusheva IF, Fomin IV, Khokhlov RA.
    Ter Arkh; 2007 Jun 25; 79(8):33-8. PubMed ID: 17926468
    [Abstract] [Full Text] [Related]

  • 8. [Does spironolactone use at arterial hypertension therapy protect endothelium also in smoking patients?].
    Kara-Perz H, Kosicka T, Perz S.
    Przegl Lek; 2009 Jun 25; 66(10):571-3. PubMed ID: 20301883
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension.
    Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E.
    Am J Hypertens; 2006 Jul 25; 19(7):750-5. PubMed ID: 16814132
    [Abstract] [Full Text] [Related]

  • 10. [Comparative effects of nifedipine and indapamide in the treatment of arterial hypertension].
    Chaignon M, Lucsko M, Rapoud JP, Aubert P, Guédon J.
    Arch Mal Coeur Vaiss; 1985 Nov 25; 78 Spec No():67-72. PubMed ID: 3937509
    [Abstract] [Full Text] [Related]

  • 11. Effect of indapamide on the renin-aldosterone system, and urinary excretion of potassium and calcium in essential hypertension.
    Danielsen H, Pedersen EB, Spencer ES.
    Br J Clin Pharmacol; 1984 Aug 25; 18(2):229-31. PubMed ID: 6386023
    [Abstract] [Full Text] [Related]

  • 12. Comparison of chlorthalidone and spironolactone in low--renin essential hypertension.
    Kreeft JH, Larochelle P, Ogilvie RI.
    Can Med Assoc J; 1983 Jan 01; 128(1):31-4. PubMed ID: 6336600
    [Abstract] [Full Text] [Related]

  • 13. [Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension].
    Tosti-Croce C, Mantellini R, Fanti P, Sciarra F.
    Minerva Med; 1983 Apr 07; 74(14-15):791-7. PubMed ID: 6339999
    [Abstract] [Full Text] [Related]

  • 14. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 07; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 15. [Exchangeable sodium, total-body potassium, plasma volume, and hypotensive effect of various diuretics in patients with essential hypertension and low plasma renin level (author's transl)].
    Distler A, Keim HJ, Philipp T, Philippi A, Walter U, Werner E.
    Dtsch Med Wochenschr; 1974 Apr 26; 99(17):864-9. PubMed ID: 4834874
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Role of renin-angiotensin-aldosterone system in pathogenesis of arterial hypertension in chronic renal failure].
    Lifshits NL, Kutyrina IM.
    Ter Arkh; 1999 Apr 26; 71(6):64-7. PubMed ID: 10420461
    [Abstract] [Full Text] [Related]

  • 19. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients.
    Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T.
    Arch Intern Med; 1981 Nov 26; 141(12):1589-93. PubMed ID: 7030245
    [Abstract] [Full Text] [Related]

  • 20. Treating hypertension by rational use of diuretics: results of the Russian ARGUS-2 Study.
    Kobalava ZD, Kotovskaya YV, Villevalde SV, Moiseev VS, ARGUS-2 Study.
    Curr Med Res Opin; 2009 Sep 26; 25(9):2229-37. PubMed ID: 19622008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.